ミッション
私たちは、イノベーション、科学的な厳密さ、誠実さに基づき、創薬及び医薬品の初期開発に取り組んでいます。そして私たちのゴールは、神経疾患の発生・進行・退縮をこれまで以上に検出できる新たな画像診断技術や、神経疾患のよりよい治療につながる新たな治療方法といった、患者さんが特に必要としている新たな価値を生み出すことにあります。
Aprinoia discovers and develops first-in-class diagnostics and therapeutics for Alzheimer’s Disease (AD) and other tau-associated neurodegenerative diseases (Tauopathies). We achieve our mission by building comprehensive internal drug discovery and development capabilities and integrative collaborations with world-class scientists, research institutions and pharmaceutical companies to bring innovative ideas and scientific discoveries to life.
Aprinoia discovers and develops first-in-class diagnostics and therapeutics for Alzheimer’s Disease (AD) and other tau-associated neurodegenerative diseases (Tauopathies). We achieve our mission by building comprehensive internal drug discovery and development capabilities and integrative collaborations with world-class scientists, research institutions and pharmaceutical companies to bring innovative ideas and scientific discoveries to life.
Tauopathies are neurodegenerative disorders caused by aggregation of Tau proteins with formations of neurofibrillary tangles.
Tau aggregates are not only found in AD, but also non-AD neurodegenerative diseases, including FTD, PSP, and CBS.
Synucleinopathies are neurodegenerative disorders caused by abnormal aggregation of alpha-synuclein proteins with formations of insoluble fibrils.
Alpha-synuclein aggregates are found in major families of synucleinopathies, which include Parkinson Disease (PD), Dementia with Lewy Bodies (DLB), and Multiple System Atrophy (MSA).
News
August 29, 2019
APRINOIA Therapeutics社は、東京の慶應義塾大学とのコラボレーションを開始しました
APRINOIA Therapeutics社（以下、アプリノイア）は、東京の慶應義塾大学とのコラボレーションを開始しました。その中でアプリノイアのタウPETイメージングトレーサー18F-APN-1607（PM-PBB3）が認知症患者のプロファイリングに使用されます。このコラボレーションは、AMED（国立研究開発法人日本医療研究開発機構）の課題番号JP17pc0101006の支援を受け慶應義塾大学とエーザイ株式会社の産医連携拠点であるエーザイ・慶應義塾大学 認知症イノベーションラボ（EKID, Eisai-Keio Innovation Laboratory for Dementia）で実施される研究の一部であります。アプリノイアは、認知症、特にアルツハイマー病の理解を深めるのに役立つ研究に貢献する機会を得たことに感謝しています。
December 27, 2018
2019 Human Amyloid Imaging Conference
APRINOIA will be presenting the latest clinical trial results for its lead Tau PET Imaging Tracer APN-1607 (PM-PBB3) at the Human Amyloid Imaging (HAI) Conference in Miami, USA in January 2019. We will deliver a total of 10 presentations with our partners.
October 11, 2018
Emerging Company Profile - APRINOIA TACKLES TAU
Aprinoia Therapeutics Inc. is developing a pipeline targeting tauopathies that includes diagnostic imaging tracers, mAbs specific to pathologic tau and small molecules that bind to tau rather than dissociate tau aggregates.
“We are going to develop imaging biomarkers for all the therapeutic targets first to see those targets, and then find therapies,” CEO Ming-Kuei Jang told BioCentury.
August 31, 2018
Asia-China: 2018 Clinical Trials on Alzheimer's Disease Conference
APRINOIA will be sponsoring the first Clinical Trials on Alzheimer's Disease Conference (CTAD) in Asia. The conference will take place in Shanghai on September 1st and 2nd. APRINOIA will be presenting the latest clinical data of our lead tau PET Imaging tracer, APN-1607 (PM-PBB3), and the current progress of our therapeutics programs at the conference.
December 14, 2017
APRINOIA Closes US$11.1 Million Series B Financing
APRINOIA has completed its US$11.1 million Series B round. The Series B round was led by KTB Network (Korea) and DCI Partners (Japan), along with participations from ShangPharma Investment Group (China) and TaiAn Technologies (Taiwan). The proceeds of the funding will be used to finance preclinical and clinical development for APRINOIA’s tau centric programs.
December 11, 2016
2017 International Conference on Alzheimer's Disease and Parkinson's Disease
APRINOIA will be presenting the first-in-the-human clinical trial result for its lead Tau PET Imaging Tracer APN-1607 (PM-PBB3) at the 13th International Conference on Alzheimer's Disease and Parkinson's Disease (AD&PD) in Vienna in March 2017.
November 19, 2016
US FDA IND
APRINOIA has received written approval from the US FDA to conduct the first-in-the-human clinical trial in the US.
Careers
This information will be updated shortly.
お問い合わせ
台灣
Email ：
地址 ： 11503 臺北市南港區園區街3號17樓
辦公室電話： +886-2-2655-8868
Taiwan
Address ： 17F, No.3, Park St., Nangang District, Taipei City 11503
Phone ： +886-2-2655-8868
------------------------------------------------------------------------------------------
中国大陆
邮箱 ：
地址 ： 苏州市工业园区星湖街218号 生物医药产业园B2号楼5楼503室 215123
办公室电话：+86-512-8777 8382
China
Address ： R503,5F,Building B2,218 Xing Hu Rd,Suzhou Industrial Park,Suzhou 215123
Phone ： +86-512-8777 8382
------------------------------------------------------------------------------------------------
日本
Email ：
所在地 ： 〒104ｰ0033 東京都中央区新川1-2-8 第5山京ビル5F
Tel ： 03-6280-4277
Japan
Address ： Shinkawa 1-2-8, Chuo-ku, Tokyo 104-0033, Japan
Phone ： +81-3-6280-4277
